<DOC>
	<DOC>NCT01943045</DOC>
	<brief_summary>The purpose of this study is to determine the safety, tolerability, and activity of NGM282 in patients with Type 2 Diabetes.</brief_summary>
	<brief_title>Phase 2 Study of NGM282 in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<criteria>Males or females, between 18 and 70 years of age, inclusive BMI range of 2440 kg/m2, inclusive No active coronary artery disease Resting heart rate in the range of 40100 bpm Diagnosis of Type 1 diabetes History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>